Angiœdèmes bradykiniques acquis non médicamenteux

[1]  M. Cicardi,et al.  Acquired C1-inhibitor deficiency and lymphoproliferative disorders: a tight relationship. , 2013, Critical reviews in oncology/hematology.

[2]  M. Triggiani,et al.  Icatibant treatment for acquired C1‐inhibitor deficiency: a real‐world observational study , 2012, Allergy.

[3]  É. Oksenhendler,et al.  Acquired C1-Inhibitor Deficiency: 7 Patients Treated with Rituximab , 2012, Journal of Clinical Immunology.

[4]  P. Pundir,et al.  Comparison of the inhibitory effects of resveratrol and tranilast on IgE, 48/80 and substance P dependent-mast cell activation , 2010, Allergy, Asthma, and Clinical Immunology : Official Journal of the Canadian Society of Allergy and Clinical Immunology.

[5]  M. Cicardi,et al.  Angioedema due to acquired C1-inhibitor deficiency: a bridging condition between autoimmunity and lymphoproliferation. , 2008, Autoimmunity reviews.

[6]  M. Levi,et al.  Rituximab-induced elimination of acquired angioedema due to C1-inhibitor deficiency. , 2006, The American journal of medicine.

[7]  O. Fain,et al.  Déficit acquis en C1 inhibiteur associé à un syndrome lymphoprolifératif : quatre observations , 2004 .

[8]  M. Cicardi,et al.  Autoantibodies and Lymphoproliferative Diseases in Acquired C1-Inhibitor Deficiencies , 2003, Medicine.

[9]  J. Piette,et al.  Prevalence of monoclonal gammopathy in patients presenting with acquired angioedema type 2. , 2002, American Journal of Medicine.

[10]  M. Kazatchkine,et al.  A new type of acquired C1 inhibitor deficiency associated with systemic lupus erythematosus. , 2001, Arthritis and rheumatism.

[11]  B. Bain,et al.  Acquired angioedema as the presenting feature of lymphoproliferative disorders of mature B‐lymphocytes , 1993, Cancer.

[12]  B. Grosbois,et al.  Déficit acquis en inhibiteur de la C1 estérase et syndromes lymphoprolifératifs malins , 1985 .

[13]  J. Dupond,et al.  Déficit acquis en inhibiteur de la C1 estérase et syndrome lymphoprolifératif , 1985 .

[14]  F. Oberling,et al.  Acquired C1 inhibitor deficiency in a case of lymphosarcoma of the spleen. Reversal of complement abnormalities after splenectomy. , 1979, Clinical and Experimental Immunology.

[15]  Y. Bertrand,et al.  Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with beta-thalassemia major. , 2006 .